News

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary ...
AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...
The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune WILMINGTON, Del., March 14, 2025--AstraZeneca and Erin Andrews have teamed up as part of a national public health ...
— We have everything you need: full data on over 800 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & ...
ROCKVILLE, Md. (DC News Now) — Montgomery County officials launched Mobilize Montgomery, a public-private partnership aimed at supporting businesses and workers affected by federal budget cuts. The ...
Also this month, AstraZeneca announced it could pay up to $1 billion on a cash and debt-free basis for Belgian company EsoBiotec to advance its cell therapy ambitions. It has agreed to acquire all ...
[HONG KONG, LONDON] Ever since AstraZeneca shocked investors in October with news its China chief was under investigation, the British pharmaceutical giant has tried to maintain a business-as-usual ...
AstraZeneca's booth is seen during an expo in Beijing in November. The pharma company announced an investment of $2.5 billion to establish a global R&D center in Beijing. CHINA DAILY Multinational ...
The PMCPA has dug into the industry’s LinkedIn activities once again. AstraZeneca received the harshest censure in the latest set of cases, taking a telling-off over one of its own posts ...
Biopharmaceutical multinational AstraZeneca is not letting a bumpy 2024 dictate its path forward in China, and in the wake of a recent controversy emerges a multibillion-dollar commitment to China ...
Learn More. After rising by over 20% since November, the AstraZeneca (LSE:AZN) share price is on a good run. And now management has just signed a $1bn deal to acquire EsoBiotec and further secure ...